Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DK4I
|
|||
| Drug Name |
PMID26560530-Compound-24
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NATIONAL CANCER CENTER KIM, Soo Youl LEE, Chang Hoon
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H22O4
|
|||
| Canonical SMILES |
CC(CC1=CC(=C(C=C1)O)O)C(C)CC2=CC(=C(C=C2)O)O
|
|||
| InChI |
1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3
|
|||
| InChIKey |
HCZKYJDFEPMADG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 500-38-9
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:7625
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.